Business Context and Reporting Period
This Form 8-K Current Report was filed by 10x Genomics, Inc. on July 10, 2024. The filing reports the appointment of a new member to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation.
Material Changes
The primary material change reported is the appointment of Sarah A. Teichmann to the Board of Directors as a Class II director, effective immediately. Her term expires at the 2027 annual meeting of stockholders or until her successor is elected.
Management Commentary and Compensation Details
The Board appointed Dr. Teichmann based on her extensive academic training, contributions to genomics, and leadership experience at institutions such as the University of Cambridge, GlaxoSmithKline, and the Wellcome Sanger Institute. Her compensation package includes:
- Annual Cash Retainer: $55,000 for Board service.
- Initial Equity Grant: A one-time grant of restricted stock units (RSUs) with a target value of $400,000, granted on August 30, 2024. Vesting begins one-third on November 21, 2025, with the remainder vesting in equal quarterly installments over the following two years.
- Annual Equity Grant: An annual grant of RSUs with a target value of $215,000, granted on the date of the annual meeting of stockholders. Vesting occurs in quarterly installments over four years.
- Committee Retainers: Eligibility for additional annual cash retainers if she serves as a member or chair of Board committees.
Dr. Teichmann has also entered into the Company's standard indemnification agreement.
Investor Verification Checklist
- Verify the vesting schedule and target value of the initial $400,000 RSU grant.
- Confirm the date of the next annual meeting of stockholders to determine the timing of the first annual $215,000 RSU grant.
- Review the Company's Non-Employee Director Compensation Policy for details on committee retainers.
- Assess Dr. Teichmann's potential conflicts of interest given her concurrent roles at GlaxoSmithKline and EnsoCell Therapeutics.